CD19 and systemic sclerosis: In a compassionate use report from Fabian Müller et al., 15 patients with severe AIDs—including 8 with SLE, 3 with idiopathic inflammatory myositis, and 4 with systemic sclerosis—were treated with anti-CD19 CAR-T cells.